UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): June 18, 2020
EXAGEN INC.
(Exact name of registrant as specified in its charter)





Delaware

001-39049

20-0434866
(State or other jurisdiction
of incorporation or organization)

(Commission
File Number)

(I.R.S. Employer
Identification No.)
1261 Liberty Way
Vista, CA 92081
(Address of principal executive offices) (Zip Code)
(760) 560-1501
(Registrant’s telephone number, include area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:





Title of each class

Trading
Symbol(s)

Name of each exchange
on which registered
Common Stock, par value $0.001 per share

XGN

The Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




Item 5.07. Submission of Matters to a Vote of Security Holders.
Exagen Inc. (the "Company") held its 2020 annual meeting of stockholders (the "Annual Meeting") on June 18, 2020. At the Annual Meeting, the Company's stockholders voted on two proposals, as described below. Each of the proposals was described in detail in the Company's definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 29, 2020. The vote totals noted below are final voting results from the Annual Meeting.
Proposal 1
The Company's stockholders elected the following three Class I directors for a three-year term of office expiring at the Company's 2023 annual meeting of stockholders and until their successors are duly elected and qualified or until such director's earlier death, resignation or removal.

Name Votes For Votes Withheld Broker Non-Votes
Brian Birk 7,038,015 613,176 757,929
Tina S. Nova, Ph.D. 7,087,448 563,743 757,929
Ebetuel Pallares, Ph.D. 7,038,230 612,961 757,929

Proposal 2
The Company's stockholders ratified the appointment of BDO USA, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020.

Votes For Votes Against Abstentions Broker Non-Votes
8,408,077 1,023 20 —



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.











EXAGEN INC.




Date: June 19, 2020



By:

/s/ Kamal Adawi






Kamal Adawi






Chief Financial Officer


Exagen (NASDAQ:XGN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Exagen Charts.
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Exagen Charts.